GlobeImmune Initiates Phase II Study

GlobeImmune, Inc. announced the initiation of a Phase II clinical trial of GI-4000, for the treatment of early-stage pancreas cancer. GI-4000 is designed to activate the immune system against cancer cells containing a mutated protein called Ras that is found in 80-90% of pancreas tumors. In a recently completed Phase 1 study of end-stage pancreas and colorectal cancer patients, GI-4000 was generally well-tolerated across the full range of doses tested.

Read the Red Herring Top 100 Start-up Companies in America article on GlobeImmune here.